Médecins pour Chimiothérapie à l'étranger — Page 5

Dr. Emad Shash is a medical oncologist who has participated in over 70 oncology clinical trials. He serves as the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. Dr. Shash specializes in systemic therapies, including chemotherapy, targeted therapy, and immunotherapy. He holds a Diploma in Hospital Quality Management and Patient Safety from JCI.

• Serves as an ESMO panel voting member and an ASCO committee member.
• Treats breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers.
• Former research physician and medical lead at the EORTC in Brussels.
• Works at Shefaa Al Orman, an ESMO-accredited oncology center treating 6,000 patients annually.

Le Dr Spielberg est un onco-hématologue spécialisé qui traite des patients au Centre Médical Assuta.

• Se concentre exclusivement sur les traitements de chimiothérapie
• Travaille dans l'un des principaux centres médicaux d'Israël
• Dédié à l'élaboration de plans de traitement personnalisés pour chaque patient

Le Dr Zhevelyuk est spécialisé en oncologie et en radiologie à l'Assuta Medical Center.

• Expérimenté dans les traitements de chimiothérapie
• Travaille dans un centre médical de premier plan
• Se concentre sur les soins centrés sur le patient

Médecin-chef du centre d'oncologie du centre médical Assuta – Le Dr Tepper est spécialisé dans le diagnostic complet des cas oncologiques.

• Vaste expérience des techniques de diagnostic de pointe
• Dirige une équipe de spécialistes en oncologie dans un centre médical renommé
• Travaille avec des équipements et des technologies de diagnostic avancés
• Se concentre sur la détection précoce et précise de divers cancers

Dr. Maha Yahia is a medical and hemato-oncologist at Shefaa Al Orman International Oncology Hospitals. She served as a Lieutenant Colonel physician in the Egyptian Armed Forces Medical Corps. Dr. Yahia specializes in treatment planning for breast, thoracic, and gastrointestinal cancers. She focuses on immunotherapy, targeted therapy, and complex chemotherapy protocols.

• Former Head of the Clinical Research Support Team at Maadi AFMC.
• Trained at the National Cancer Institute, Cairo University, in hemato-oncology.
• Treats genitourinary, gynecologic, and rare cancers alongside hematologic conditions.
• Works at an ESMO-accredited center that treats 6,000 patients annually.

Dr. Raanan Berger is the Director of the Cancer Center at Sheba Medical Center. He was listed in Forbes Israel’s “Best Doctors” in 2025. Dr. Berger specializes in genitourinary oncology and radiates complex prostate tumors. He completed a postdoctoral fellowship at the Dana-Farber/Harvard Cancer Institute.

• Heads the clinical research unit focusing on molecular oncology.
• Co-authored over 20 peer-reviewed papers on prostate cancer and BRCA mutations.
• Member of the American Society of Clinical Oncology (ASCO).
• Performs systemic therapy and radiotherapy at a Top-10 globally ranked hospital.

Dr. Eytan Aharon Ben-Ami leads the Oncology Division at Sheba Medical Center in Israel. He specialized in sarcoma and bone oncology at the Dana-Farber Cancer Institute. Dr. Ben-Ami founded the Sheba Clinical Research Organization to advance cancer studies. He treats rare bone tumors and soft tissue sarcomas with personalized protocols.

• Heads the Early-Phase Clinical Trials Unit for innovative cancer therapies.
• Authored over 40 scientific publications on molecular mechanisms and early detection.
• Leads Phase I trials in targeted therapy and immunotherapy for rare cancers.
• Works at Sheba Medical Center, a top-10 hospital globally per Newsweek.

Dr. Iris Kventsel is a pediatric hemato-oncologist and bone marrow transplant specialist at Sheba Medical Center. She treats childhood sarcomas like Ewing sarcoma and osteosarcoma at the Edmond and Lily Safra Children’s Hospital. Dr. Kventsel integrates targeted therapies with cellular treatments for complex childhood cancers. She serves on the academic staff at Tel Aviv University Faculty of Medicine.

• Specializes in bone marrow transplantation and CAR T-cell therapy for pediatric patients.
• Researches genetic cancer predisposition, including Li-Fraumeni syndrome and susceptibility genes.
• Published in major journals on stem cell biology and surgical oncology (HIPEC).
• Works at Sheba Medical Center, ranked among the world’s top 10 hospitals.

Dr. Lucía González Cortijo is the Head of Medical Oncology at Hospital Universitario Quirónsalud Madrid. She specializes in breast and gynecologic cancers, including ovarian and cervical malignancies. Dr. González Cortijo holds a PhD cum laude and a Master’s in Molecular Oncology. She focuses on precision oncology, immunotherapy, and targeted treatments.

• Principal Investigator in over 20 Phase II–III clinical trials.
• Participated as a sub-investigator in more than 50 international trials.
• Member of the American Society of Clinical Oncology (ASCO) and ESMO.
• Founder of the La Vida en Rosa Foundation for women with cancer.

Dr. Mehmet Salih Iyikesici is a medical oncologist at Central Hospital in Istanbul. He specializes in metabolic supported chemotherapy (MSCT) for breast, lung, and gastrointestinal cancers. Dr. Iyikesici integrates ketogenic diets and hyperbaric oxygen therapy into cancer care cycles.

• Published peer-reviewed research on MSCT outcomes specifically for rectal cancer.
• Treats complex cases of pancreatic and colorectal cancer using hyperthermia therapy.
• Contributes to international scientific studies on early-stage breast cancer survival.
• Practices at a clinic equipped with AI-powered MRI and CT imaging systems.

Dr. Hila Magen is a leading Israeli hemato-oncologist at Sheba Medical Center. She heads the Multiple Myeloma and Amyloidosis Unit. Dr. Magen specializes in treating complex plasma cell disorders and high-risk myeloma. She is a principal investigator for innovative point-of-care CAR-T therapy programs. Her work brings advanced immunotherapies into routine clinical care.

• Authored over 100 scientific publications and landmark myeloma studies.
• Completed fellowships at MD Anderson and University of Arkansas for Medical Sciences.
• Performs CAR-T cell therapy and bone marrow transplantations.
• Works at Sheba Medical Center, ranked 7th worldwide in 2026 by Newsweek.

Dr. Avichai Shimoni is the Director of Bone Marrow Transplantation at Sheba Medical Center. He treats complex blood cancers. He completed a specialized fellowship at the MD Anderson Cancer Center. Dr. Shimoni uses allogeneic and autologous transplants for high-risk patients. He is a professor and Chairman of Hematology at Tel Aviv University.

• Named among Israel’s Best Doctors by Forbes for 2025 and 2026.
• Authored over 250 scientific papers on cellular therapies and transplantation.
• Provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma.
• Works at Sheba Medical Center, a top-10 hospital globally per Newsweek.

Dr. Abraham Avigdor is the Director of the Institute of Hematology at Sheba Medical Center. He is a global authority on lymphoma, CAR-T therapy, and complex blood cancers. Dr. Avigdor founded the Israeli Lymphoma Working Group. He helps lead a clinic ranked 7th worldwide by Newsweek in 2026.

• Authored over 130 scientific publications on hemato-oncology and cellular therapy.
• Pioneered the integration of CAR-T cell therapy for lymphoma and myeloma.
• Leads allogeneic and autologous bone marrow transplantation programs.
• Served as the Chairman of the Israeli Lymphoma Study Group.

Dr. Jair Bar is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He specializes in treating advanced non-small cell lung cancer using personalized immunotherapy and targeted treatments. Dr. Bar holds a PhD in Molecular Biology and leads a research lab focused on immunotherapy resistance.

• Chair of the Israel Lung Cancer Group.
• Board-certified in both Medical Oncology and Radiotherapy Oncology.
• Treats patients at Sheba Medical Center, a top-10 globally ranked hospital.
• Uses molecular and genetic profiling to create precise cancer treatment plans.

Dr. Beni Boursi is a leading oncologist at Sheba Medical Center. He founded the ECOG-ACRIN Microbiome Working Group. He specializes in treating gastrointestinal cancers using innovative microbial modulation. Dr. Boursi is board certified in internal medicine and medical oncology. He earned his medical degree with highest honors from Tel Aviv University.

• Completed oncology fellowships at the University of Pennsylvania.
• Trained in medical oncology at MD Anderson and Mayo Clinic.
• Developed predictive models for early colorectal and pancreatic cancer diagnosis.
• Published research on microbiome-oncology in the prestigious journal Science.

322 publications évaluées par des pairs – Le Prof. Kuemmel dirige la recherche et le diagnostic du cancer du sein aux Kliniken Essen-Mitte.

• Directeur clinique d'une unité de sénologie multidisciplinaire
• Membre de la faculté ESMO pour le cancer du sein
• Membre du conseil d'administration de l'AGO (Groupe allemand d'oncologie gynécologique)
• Plus de 1 000 conférences sur invitation sur des sujets liés au cancer du sein

Directeur/Directrice du Centre de traitement du cancer du sein – Le/La Professeur(e) Jablonski-Perec apporte des décennies d'expertise spécialisée au Centre médical Hadassah.

• Formation médicale reçue au Sloan-Kettering Cancer Center de New York
• Professeur(e) d'oncologie à l'Université hébraïque depuis 2006
• Ancien/Ancienne directeur(trice) de l'Institut d'oncologie
• Membre de multiples sociétés internationales d'oncologie

Expert de premier plan en leucémie lymphoïde chronique (LLC) – Le Professeur Bosch a été le pionnier de nouveaux traitements et technologies pour les maladies hématologiques.

• Mène plus de 80 essais cliniques de phase 1 à phase 3
• A publié plus de 100 articles dans les meilleures revues médicales
• Chef du service d'Hématologie à l'Institut d'Oncologie IOB
• Président du groupe espagnol d'étude de la LLC (GELLC)

Investigatrice principale dans les essais cliniques sur les cancers de l'ovaire, du col de l'utérus et de l'endomètre – la Dre Oaknin dirige une recherche pionnière à l'Hospital Quiron Barcelona.

• Auteure de plus de 100 publications sur les tumeurs gynécologiques
• Membre du conseil exécutif du Groupe GEICO (Groupe espagnol de recherche sur le cancer de l'ovaire)
• Membre du corps professoral pour le Gyn-Track de l'ESMO
• Représentante espagnole au Comité cervical du Groupe GCIG